UPDATE: Treating COVID-19 in PD and other Movement Disorders: A Review of Drug Interactions

Presented by

Mónica M. Kurtis, MD and Pablo Mir, MD, PhD

Course Description

This is an update to the webinar published on June 5, 2020.

As the number of people infected by SARS-CoV-2 continues to rise, it is our responsibility to learn how this universal health crisis can impact Movement Disorder patients’ care. There are a number of experimental treatments being used to treat COVID-19, based on repurposed drugs and more recent antivirals and inmunomodulators. The mechanisms of action and side effects of these drugs vary widely and may interact with treatments of some neurological disorders, such as Parkinson’s disease and other movement disorders. To date, there is no data suggesting that PD, or any other movement disorder, increases the risk of developing COVID-19. However, movement disorder patients may have an increased risk of infection if living in nursing homes and may develop severe disease due to advanced age or comorbid diseases (i.e. hypertension or diabetes).

This course will discuss possible pharmacological interactions between experimental COVID-19 drugs and the established treatments used in PD, tremor, dystonia, chorea and tics. Further, this course will provide guidelines to Movement Disorders specialists as well as general neurologists to ensure that their patients with COVID-19 are treated safely. Necessary drug adjustments will be discussed for each movement disorder drug and also for drugs that are commonly used to treat non motor symptoms in movement disorder patients such as GI problems, psychiatric comorbidities, dementia, and insomnia. Finally, some clinical cases will be put forth to discuss potential problems and possible solutions.

Target Audience

Movement Disorders specialists, Movement Disorders fellows, general neurologists, neurology residents, and general practitioners.

Learning Objectives
  1. Identify possible interactions between COVID-19 drugs and PD medication
  2. Adjust dopaminergic therapy in PD patients with COVID-19
  3. Provide safe and accurate information to patients and other physician during the COVID-19 pandemic


MDS OnDemand Webinars


Related Resources

Webinar Slides – UPDATE: Treating COVID-19 in PD and other Movement Disorders: A Review of Drug Interactions (Kurtis)(pdf)

 

Top

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice